Should I buy or sell Neurocrine Biosciences stock right now?

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 6 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NBIX shares. View NBIX analyst ratings or view top-rated stocks .

What is Neurocrine Biosciences' stock price target for 2024?

22 Wall Street research analysts have issued 12-month price targets for Neurocrine Biosciences' stock. Their NBIX share price targets range from $100.00 to $165.00. On average, they expect the company's stock price to reach $139.67 in the next year. This suggests a possible upside of 5.4% from the stock's current price. View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts .

How have NBIX shares performed in 2024?

Neurocrine Biosciences' stock was trading at $131.76 at the beginning of the year. Since then, NBIX stock has increased by 0.6% and is now trading at $132.54. View the best growth stocks for 2024 here .

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our NBIX earnings forecast .

How can I listen to Neurocrine Biosciences' earnings call?

Neurocrine Biosciences will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings results on Wednesday, February, 7th. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.31. The business had revenue of $515.20 million for the quarter, compared to analysts' expectations of $518.52 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 12.85% and a net margin of 13.23%. The business's revenue for the quarter was up 25.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.88 EPS.

What ETFs hold Neurocrine Biosciences' stock?

ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) , iShares Neuroscience and Healthcare ETF (IBRN) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Goldman Sachs Future Health Care Equity ETF (GDOC) , Virtus LifeSci Biotech Products ETF (BBP) , VictoryShares Nasdaq Next 50 ETF (QQQN) , American Century STOXX U.S. Quality Growth ETF (QGRO) and Invesco S&P MidCap Momentum ETF (XMMO) .

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com . Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA) , Gilead Sciences (GILD) , Micron Technology (MU) , Alibaba Group (BABA) , Netflix (NFLX) , AbbVie (ABBV) , Walt Disney (DIS) , Tesla (TSLA) , Block (SQ) and Salesforce (CRM) .

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.51%), Los Angeles Capital Management LLC (0.25%), Portman Square Capital LLP (0.00%), Sendero Wealth Management LLC (0.02%), Tealwood Asset Management Inc. (0.01%) and Park Avenue Securities LLC (0.01%). Insiders that own company stock include Darin Lippoldt , David W Boyer , Dimitri E Grigoriadis , Eiry Roberts , Eric Benevich , Gary A Lyons , George J Morrow, Ingrid Delaet , Jude Onyia , Julie Cooke , Kevin Charles Gorman , Kyle Gano , Leslie V Norwalk, Malcolm Lloyd-Smith , Matt Abernethy , Neurocrine Biosciences Inc, Richard F Pops , Stephen A Sherwin and William H Rastetter . View institutional ownership trends .

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NBIX

Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free NBIX Stock Alerts

$132.54

-0.69 (-0.52%)

(As of 04/18/2024 ET)

Compare

Today's Range: $131.00
▼
$134.20
50-Day Range: $130.40
▼
$143.74
52-Week Range: $89.04
▼
$148.37

Volume: 549,307 shs
Average Volume: 847,477 shs
Market Capitalization: $13.19 billion

P/E Ratio: 54.77
Dividend Yield: N/A
Price Target: $139.67

Get Neurocrine Biosciences alerts:

Neurocrine Biosciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.73 Rating Score
Upside/Downside: 5.4% Upside
$139.67 Price Target
Short Interest: Healthy
2.44% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.61
Upright™ Environmental Score
News Sentiment: 0.63
Based on 15 Articles This Week
Insider Trading: Selling Shares
$27.21 M Sold Last Quarter
Proj. Earnings Growth: 28.72%
From $4.84 to $6.23 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.39 out of 5 stars

Medical Sector

105th out of 918 stocks

Biological Products, Except Diagnostic Industry

11th out of 150 stocks

2.4

Analyst's Opinion

Consensus Rating
Neurocrine Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 16 buy ratings, 6 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Neurocrine Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
2.44% of the outstanding shares of Neurocrine Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Neurocrine Biosciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Neurocrine Biosciences has recently decreased by 2.02%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Neurocrine Biosciences does not currently pay a dividend.
Dividend Growth
Neurocrine Biosciences does not have a long track record of dividend growth.

2.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Neurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.
Environmental Sustainability
The Environmental Impact score for Neurocrine Biosciences is -2.61.

2.6

News and Social Media Coverage

News Sentiment
Neurocrine Biosciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for Neurocrine Biosciences this week, compared to 8 articles on an average week.
Search Interest
Only 4 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.
MarketBeat Follows
Only 8 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -65% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,205,009.00 in company stock.
Percentage Held by Insiders
Only 4.40% of the stock of Neurocrine Biosciences is held by insiders.
Percentage Held by Institutions
92.59% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Neurocrine Biosciences are expected to grow by 28.72% in the coming year, from $4.84 to $6.23 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Neurocrine Biosciences is 54.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.54.
Price to Earnings Ratio vs. Sector
The P/E ratio of Neurocrine Biosciences is 54.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 231.05.
Price to Book Value per Share Ratio
Neurocrine Biosciences has a P/B Ratio of 5.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

Go here now for this breaking story.

About Neurocrine Biosciences Stock (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

NBIX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NBIX Stock News Headlines

April 18, 2024 | insidertrades.com

Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 19,818 Shares of Stock

April 16, 2024 | insidertrades.com

The 5 Stocks Most Sold By Insiders This Year (NBIX)

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 26, 2024 | insidertrades.com

Ingrid Delaet Sells 5,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

April 18, 2024 | investing.com

Sentia and Neurocrine extend collaboration on peptide therapeutics

April 17, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - NBIX

April 16, 2024 | globenewswire.com

Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568

April 15, 2024 | americanbankingnews.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Rating of "Moderate Buy" from Analysts

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 13, 2024 | americanbankingnews.com

Research Analysts Set Expectations for Neurocrine Biosciences, Inc.'s Q1 2024 Earnings (NASDAQ:NBIX)

April 11, 2024 | americanbankingnews.com

Neurocrine Biosciences' (NBIX) Overweight Rating Reaffirmed at Cantor Fitzgerald

April 10, 2024 | prnewswire.com

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results

April 5, 2024 | uk.investing.com

Neurocrine begins phase 2 trial for depression drug

April 5, 2024 | investing.com

Neurocrine Biosciences executive sells shares worth over $37k

April 3, 2024 | markets.businessinsider.com

Wells Fargo Reaffirms Their Hold Rating on Neurocrine (NBIX)

April 3, 2024 | finance.yahoo.com

Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Performance Tethered To Its Attractive Financial Prospects?

April 3, 2024 | prnewswire.com

Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

March 28, 2024 | finance.yahoo.com

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

March 23, 2024 | finance.yahoo.com

S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind

March 17, 2024 | uk.investing.com

Neurocrine Biosciences director sells $5.58m in stock

March 17, 2024 | uk.investing.com

Neurocrine Biosciences exec sells shares worth over $420k

March 17, 2024 | investing.com

Neurocrine Biosciences director pops Richard F sells $3.26M in stock

March 16, 2024 | finance.yahoo.com

Director Richard Pops Sells 23,200 Shares of Neurocrine Biosciences Inc (NBIX)

March 16, 2024 | finance.yahoo.com

Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells 3,000 Shares

March 16, 2024 | finance.yahoo.com

AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base

March 15, 2024 | finance.yahoo.com

Neurocrine Biosciences Is Pioneering Therapies for Neurological Disorders

March 14, 2024 | finance.yahoo.com

NBIX Apr 2024 145.000 call

See More Headlines

Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/07/2024
Today: 4/18/2024
Next Earnings (Confirmed): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:NBIX
CUSIP: 64125C10
CIK: 914475
Web: www.neurocrine.com
Phone: (858) 617-7600
Fax: 858-617-7602
Employees: 1,400
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $139.67
High Stock Price Target: $165.00
Low Stock Price Target: $100.00
Potential Upside/Downside: +5.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.73
Research Coverage: 22 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.42
Trailing P/E Ratio: 54.77
Forward P/E Ratio: 27.38
P/E Growth: N/A
Net Income: $249.70 million
Net Margins: 13.23%
Pretax Margin: 17.60%
Return on Equity: 12.85%
Return on Assets: 9.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.45
Quick Ratio: 2.40

Sales & Book Value

Annual Sales: $1.89 billion
Price / Sales: 6.99
Cash Flow: $2.57 per share
Price / Cash Flow: 51.56
Book Value: $22.72 per share
Price / Book: 5.83

Miscellaneous

Outstanding Shares: 99,510,000
Free Float: 95,129,000
Market Cap: $13.19 billion
Optionable: Optionable
Beta: 0.25

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Kevin C. Gorman Ph.D. (Age 66)
CEO & Director
Comp: $1.9M
Mr. Matthew C. Abernethy (Age 43)
Chief Financial Officer
Comp: $1.04M
Mr. Darin M. Lippoldt Esq. (Age 58)
Chief Legal Officer & Corporate Secretary
Comp: $921.01k
Mr. Kyle W. Gano Ph.D. (Age 51)
Chief Business Development & Strategy Officer
Comp: $921.52k
Dr. Eiry Wyn Roberts M.D. (Age 59)
Chief Medical Officer
Comp: $1.04M
Dr. Jude Onyia Ph.D. (Age 59)
Chief Scientific Officer
Comp: $621.66k
Jane Sorensen
Head of Investor Relations
Ms. Julie S. Cooke (Age 58)
Chief Human Resources Officer
Mr. Eric S. Benevich (Age 59)
Chief Commercial Officer
Comp: $805k
Mr. David Warren Boyer (Age 44)
Chief Corporate Affairs Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NBIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?: 22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 6 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NBIX shares.
View NBIX analyst ratings or view top-rated stocks.
What is Neurocrine Biosciences' stock price target for 2024?: 22 Wall Street research analysts have issued 12-month price targets for Neurocrine Biosciences' stock. Their NBIX share price targets range from $100.00 to $165.00. On average, they expect the company's stock price to reach $139.67 in the next year. This suggests a possible upside of 5.4% from the stock's current price.
View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts.
How have NBIX shares performed in 2024?: Neurocrine Biosciences' stock was trading at $131.76 at the beginning of the year. Since then, NBIX stock has increased by 0.6% and is now trading at $132.54.
View the best growth stocks for 2024 here.
When is Neurocrine Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our NBIX earnings forecast.
How can I listen to Neurocrine Biosciences' earnings call?: Neurocrine Biosciences will be holding an earnings conference call on Wednesday, May 1st at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Neurocrine Biosciences' earnings last quarter?: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings results on Wednesday, February, 7th. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.31. The business had revenue of $515.20 million for the quarter, compared to analysts' expectations of $518.52 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 12.85% and a net margin of 13.23%. The business's revenue for the quarter was up 25.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.88 EPS.

What ETFs hold Neurocrine Biosciences' stock?: ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), Virtus LifeSci Biotech Products ETF (BBP), VictoryShares Nasdaq Next 50 ETF (QQQN), American Century STOXX U.S. Quality Growth ETF (QGRO) and Invesco S&P MidCap Momentum ETF (XMMO).
What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?: 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Neurocrine Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).
Who are Neurocrine Biosciences' major shareholders?: Neurocrine Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.51%), Los Angeles Capital Management LLC (0.25%), Portman Square Capital LLP (0.00%), Sendero Wealth Management LLC (0.02%), Tealwood Asset Management Inc. (0.01%) and Park Avenue Securities LLC (0.01%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, George J Morrow, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Leslie V Norwalk, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends.
How do I buy shares of Neurocrine Biosciences?: Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NBIX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Neurocrine Biosciences (NBIX) Stock Price, News & Analysis

Neurocrine Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Neurocrine Biosciences Stock (NASDAQ:NBIX)

NBIX Stock Price History

NBIX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NBIX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™